The Digital Health Podcast with Fexingo: Wearables, Diagnostics, and Health Software

Lucas and Luna explore the rise of continuous glucose monitors as a consumer wellness subscription, not just a diabetes tool. They examine how companies like Levels, Nutrisense, and Signos are marketing CGMs to biohackers and healthy people, what the data actually shows about non-diabetic glucose spikes, and whether the $200–$400 monthly subscription is backed by solid science. The episode also touches on the regulatory gray area the FDA is now scrutinizing and what this means for the future of personalized nutrition. No hype, just the numbers and the open questions.

#ContinuousGlucoseMonitor #CGM #LifestyleMedicine #WearableTech #Biohacking #PersonalizedNutrition #BloodSugar #LevelsHealth #Nutrisense #Signos #FDA #HealthTech #SubscriptionBusiness #Business #Technology #FexingoBusiness #BusinessPodcast #TheDigitalHealthPodcast

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how artificial intelligence is transforming health insurance from a reactive claims processor into a proactive health partner. They focus on one specific case: how a major insurer used AI to analyze members' smartwatch data and predict hospitalization risk 30 days in advance, cutting preventable admissions by 18 percent. The episode drills into the numbers, the algorithm's design, and the ethical trade-offs around data privacy and premium adjustments. Lucas shares how the AI model was trained on de-identified step counts and sleep patterns, while Luna raises the question of whether healthier members might subsidize those who opt out of data sharing. No hype, just the real mechanics and implications for the future of digital health.

#HealthInsurance #AI #Smartwatch #PredictiveAnalytics #PreventiveCare #Hospitalization #DataPrivacy #DigitalHealth #Wearables #HealthTech #Business #Technology #FexingoBusiness #BusinessPodcast #TheDigitalHealthPodcast #LucasAndLuna #InsuranceInnovation #RiskPrediction

Keep every episode free: buymeacoffee.com/fexingo

Episode 95 of The Digital Health Podcast explores the cutting-edge link between sleep architecture and mental health diagnostics. Lucas and Luna dive into how researchers at the University of Colorado Boulder have trained AI models to detect major depressive disorder with 80 percent accuracy using only overnight heart rate and movement data from wearables like the Oura Ring and Fitbit. They unpack a 2025 study published in JAMA Psychiatry that tracked over 10,000 participants, showing how disrupted sleep stages — particularly reduced REM latency and fragmented deep sleep — serve as biomarkers for depression. The hosts discuss the implications for passive mental health screening, the risk of false positives, and whether this technology could eventually replace the Patient Health Questionnaire-9. They also touch on the ethics of insurers accessing sleep data and the potential for early intervention in adolescents. A concrete, numbers-driven look at how your bed is becoming a diagnostic tool.

#AI #MentalHealth #Depression #Sleep #Wearables #DigitalHealth #OuraRing #Fitbit #JAMAPsychiatry #SleepArchitecture #Biomarkers #MachineLearning #HealthTech #PassiveScreening #UniversityOfColorado #PHQ9 #Ethics #FexingoBusiness

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna dive into the emerging world of AI-driven precision oncology. They focus on a concrete case: how a startup called PathAI is using deep learning to analyze tumor biopsy slides and genomic data in hours instead of weeks, matching patients to targeted therapies with higher accuracy. Lucas explains the specific technology behind digital pathology — convolutional neural networks trained on millions of annotated pathology images — and how that translates into a 30 percent reduction in false negatives for certain breast cancer subtypes. Luna challenges the cost and accessibility barriers, noting that only 15 percent of US hospitals currently use any AI-assisted pathology. They also touch on a recent study from Memorial Sloan Kettering showing that an AI model outperformed a panel of human pathologists in predicting immunotherapy response for non-small cell lung cancer patients. The episode closes with a reflection on what the next five years might look like as these models move from clinical trials into routine care.

#PrecisionOncology #PathAI #DigitalPathology #AIinMedicine #CancerTreatment #TumorDNA #DeepLearning #HealthcareAI #Business #Technology #FexingoBusiness #BusinessPodcast #MemorialSloanKettering #Immunotherapy #LungCancer #ClinicalDecisionSupport #Genomics #MedTech

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how researchers are using machine learning on voice recordings to detect early signs of postpartum depression. They discuss a 2025 study from the University of Vermont that achieved 87% accuracy by analyzing pitch variability, speech rate, and vocal jitter in just 30-second voice samples. The episode covers how this could enable routine screening in pediatrician offices and telehealth visits, reaching mothers who might not seek traditional mental health care. They also touch on privacy concerns and the potential for real-world deployment within the next two years.

#PostpartumDepression #VoiceAnalysis #AIinHealthcare #MentalHealth #MaternalHealth #DigitalHealth #MachineLearning #VoiceBiomarkers #UniversityOfVermont #ScreeningTool #Telehealth #BehavioralHealth #DeepLearning #PitchVariability #VocalJitter #Business #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how deep learning models are turning smartphone photos into triage tools for melanoma and other skin cancers. They unpack the FDA clearance of a direct-to-consumer app from the company Skin Analytics in early 2026, walk through the study data behind its sensitivity rate of 96.3 percent for detecting malignant lesions, and debate where these tools fit alongside dermatologists. The conversation covers common failure modes like lighting variability and rare cancer subtypes, how tele-dermatology partnerships are expanding access in rural areas, and why regulators are cautiously optimistic. A practical look at what works, what doesn't, and what it means for the future of at-home diagnostics.

#SkinCancer #AI #DeepLearning #Dermatology #Melanoma #SkinAnalytics #FDA #SmartphoneDiagnostics #TeleDermatology #HealthcareAI #MedicalImaging #DigitalHealth #Business #Technology #FexingoBusiness #BusinessPodcast #HealthTech #EarlyDetection

Keep every episode free: buymeacoffee.com/fexingo

In this episode, Lucas and Luna explore how AI models are using smartwatch sensor data—heart rate, skin temperature, sleep patterns—to detect early signs of COVID-19 days before symptoms appear. They dive into a specific study from Mount Sinai Health System that used the Apple Watch to catch infections with 90% sensitivity, and discuss the broader implications for wearable-based pandemic surveillance. The conversation covers the technical challenges of training AI on noisy consumer-grade data, the privacy trade-offs of continuous health monitoring, and why this approach could transform how we handle future outbreaks. Lucas and Luna also touch on the role of the FDA's digital health pre-certification program in speeding up approval for such algorithms. Specific numbers include the study's 84% specificity, the 7-day pre-symptomatic detection window, and the 500,000 participants in the ongoing DETECT study by Scripps Research.

#ArtificialIntelligence #Smartwatch #COVID19 #WearableTech #DigitalHealth #MachineLearning #AppleWatch #MountSinai #ScrippsResearch #FDA #Biometrics #PandemicSurveillance #HeartRate #SleepTracking #HealthTech #Business #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

In this episode of The Digital Health Podcast, Lucas and Luna explore how artificial intelligence is turning smartphone cameras into clinical-grade ultrasound devices. They focus on Butterfly Network's latest handheld probe and the role of deep learning in image reconstruction, making diagnostic imaging accessible in rural clinics and ambulances. The hosts discuss the regulatory hurdles, the shift from 40,000-dollar cart-based machines to 2,000-dollar pocket devices, and what this means for global health equity. They also touch on competing technologies from GE and Philips, and the surprising bottleneck: not the hardware, but the shortage of trained sonographers. A concrete look at how AI is democratizing one of medicine's most powerful diagnostic tools.

#ButterflyNetwork #SmartphoneUltrasound #AIMedicalImaging #PointOfCareUltrasound #DeepLearning #DigitalHealth #HealthTech #MedicalDevices #DiagnosticImaging #GlobalHealth #Sonography #AIinMedicine #Business #Technology #FexingoBusiness #BusinessPodcast #DigitalHealthPodcast #HealthInnovation

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how synthetic control arms—using AI to match historical patient data instead of recruiting a separate placebo group—are accelerating clinical trials and cutting costs. They break down the real-world case of a mid-stage oncology trial that used a synthetic arm built from over 10,000 historical records, reducing enrollment time by 40% and saving an estimated $12 million. The hosts discuss the regulatory stance from the FDA, the limitations when diseases are rare, and why this approach hasn't yet replaced traditional randomized controlled trials for first-line approvals. A practical look at one of the most promising data-driven shifts in clinical research.

#SyntheticControlArms #ClinicalTrials #AIinHealthcare #DrugDevelopment #FDA #Oncology #HistoricalControls #RareDiseases #TrialDesign #PatientRecruitment #Biostatistics #Pharmaceuticals #RegulatoryScience #DigitalHealth #MachineLearning #BusinessAndTechnology #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

Finding the right clinical trial is notoriously slow — fewer than 5 percent of eligible cancer patients ever enroll, and matching often takes weeks of manual chart review. But a new wave of AI-powered matching platforms is changing that. In this episode, Lucas and Luna look at how natural language processing and graph-based reasoning are scanning electronic health records and trial protocols to find matches in minutes instead of days. They focus on one startup, TrialPath, that recently reported matching 40 percent of eligible patients at a major academic medical center — up from the typical 3 to 5 percent. Lucas explains how the AI reads both structured data like lab values and unstructured doctor's notes, then weighs inclusion and exclusion criteria with a precision that rivals human coordinators. Luna asks whether this technology could widen disparities if it only reaches well-resourced hospitals, and Lucas digs into the business model — charging a per-match fee rather than a licensing or SaaS subscription. They also discuss the FDA's evolving stance on AI in clinical research, and the quiet regulatory sandbox program that let TrialPath validate its model without running afoul of patient privacy rules.

#ClinicalTrials #AIinHealth #TrialPath #PrecisionMedicine #NLP #HealthTech #PatientRecruitment #GraphAI #FDA #CancerTrials #Business #Technology #DigitalHealth #Podcast #BusinessPodcast #FexingoBusiness #ArtificialIntelligence #HealthcareInnovation

Keep every episode free: buymeacoffee.com/fexingo